A large-scale method for the selective depletion of αβ T lymphocytes from PBSC for allogeneic transplantation

References

• Filipovich AH, McGlave P, Ramsay NK, et al. Treatment of donor bone marrow with OKT3 (PAN-T monoclonal antibody) for prophylaxis of graft-vs.-host disease (GvHD) in histocompatible allogeneic bone marrow transplantation (BMT): a pilot study. J Clin Immunol 1982; 2: 154S–7S
   Google Scholar
• Filipovich AH, Vallera DA, Youle RJ, et al. Graft-versus-host disease prevention in allogeneic bone marrow transplantation from histocompatible siblings. A pilot study using immunotoxins for T cell depletion of donor bone marrow. Transplantation 1987; 44: 62–9
   PubMed Web of Science ®Google Scholar
• Martin PJ, Hansen JA, Torok-Storb B, et al. Effects of treating marrow with a CD3-specific immunotoxin for prevention of acute graft-versus-host disease. Bone Marrow Transplant 1988; 3: 437–44
   PubMed Web of Science ®Google Scholar
• Schumm M, Lang P, Taylor G, et al. Isolation of highly purified autologous and allogeneic peripheral CD34+ cells using the CliniMACS device. J Hematother 1999; 8: 209–18
   PubMedGoogle Scholar
• Lang P, Schumm M, Taylor G, et al. Clinical scale isolation of highly purified peripheral CD34+ progenitors for autologous and allogeneic transplantation in children. Bone Marrow Transplant 1999; 24: 583–9
   PubMed Web of Science ®Google Scholar
• Handgretinger R, Klingebiel T, Lang P, et al. Megadose transplantation of purified peripheral blood CD34(+) progenitor cells from HLA-mismatched parental donors in children. Bone Marrow Transplant 2001; 27: 777–83
   PubMed Web of Science ®Google Scholar
• Platzbecker U, Ehninger G, Bornhauser M. Allogeneic transplantation of CD34+ selected hematopoietic cells: clinical problems and current challenges. Leuk Lymphoma 2004; 45: 447–53
   PubMed Web of Science ®Google Scholar
• Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555–62
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Mancusi A, Capanni M, et al. Exploitation of alloreactive NK cells in adoptive immunotherapy of cancer. Curr Opin Immunol 2005; 17: 211–17
   PubMed Web of Science ®Google Scholar
• Gordon PR, Leimig T, Mueller I, et al. A large-scale method for T cell depletion: towards graft engineering of mobilized peripheral blood stem cells. Bone Marrow Transplant 2002; 30: 69–74
   PubMed Web of Science ®Google Scholar
• Benaim, E, Hale, G, Horwitz, EM, , et al. Reduced-intensity conditioning (RIC) in haploidentical transplantation [abstract]. Blood 2005;104.
   Google Scholar
• Doherty PC. The function of gamma delta T cells. Br J Haematol 1992; 81: 321–4
   PubMed Web of Science ®Google Scholar
• Drobyski WR, Majewski D, Hanson G. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease. Biol Blood Marrow Transplant 1999; 5: 222–30
   Google Scholar
• Lamb LS, Jr, Henslee-Downey PJ, Parrish RS, et al. Increased frequency of TCR gamma delta+ T cells in disease-free survivors following T cell-depleted, partially mismatched, related donor bone marrow transplantation for leukemia. J Hematother 1996; 5: 503–9
   PubMedGoogle Scholar
• Schilbach K, Geiselhart A, Handgretinger R. Induction of proliferation and augmented cytotoxicity of gammadelta T lymphocytes by bisphosphonate clodronate. Blood 2001; 97: 2917–18
   PubMedGoogle Scholar
• Blazar BR, Taylor PA, Bluestone JA, Vallera DA. Murine gamma/delta-expressing T cells affect alloengraftment via the recognition of nonclassical major histocompatibility complex class Ib antigens. Blood 1996; 87: 4463–72
   PubMed Web of Science ®Google Scholar
• Shultz LD, Lyons BL, Burzenski LM, et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R{gamma}null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 2005; 174: 6477–89
   PubMed Web of Science ®Google Scholar
• Ho VT, Soiffer RJ. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 2001; 98: 3192–204
   PubMed Web of Science ®Google Scholar
• Lang P, Klingebiel T, Bader P, et al. Transplantation of highly purified peripheral-blood CD34+ progenitor cells from related and unrelated donors in children with nonmalignant diseases. Bone Marrow Transplant 2004; 33: 25–32
   Google Scholar
• Barfield RC, Otto M, Houston J, et al. A one-step large-scale method for T- and B-cell depletion of mobilized PBSC for allogeneic transplantation. Cytotherapy 2004; 6: 1–6
   PubMed Web of Science ®Google Scholar
• Sims-Poston L, Handgretinger R, Eldridge PW. Graft composition of Clinimacs system T-cell depleted HPC-A used for transplant [abstract]. Cytotherapy 2005; 5: 35
   Google Scholar
• Leung W, Iyengar R, Turner V, et al. Determinants of antileukemia effects of allogeneic NK cells. J Immunol 2004; 172: 644–50
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097–100
   PubMed Web of Science ®Google Scholar
• Uffermann-Gretzinger S, Lossos IS, Vayntrub TA, et al. Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients. Blood 2002; 99: 1442–8
   Google Scholar
• Lamb LS, Jr, Lopez RD. Gammadelta T cells: a new frontier for immunotherapy?. Biol Blood Marrow Transplant 2005; 11: 161–8
   PubMed Web of Science ®Google Scholar
• Champlin RE, Passweg JR, Zhang MJ, et al. T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. Blood 2000; 95: 3996–4003
   PubMed Web of Science ®Google Scholar
• Keever-Taylor CA, Craig A, Molter M, et al. Complement-mediated T-cell depletion of bone marrow: comparison of T10B9.1A-31 and Muromonab-Orthoclone OKT3. Cytotherapy 2001; 3: 467–81
   Web of Science ®Google Scholar
• Borst J, van Dongen JJ, de Vries E, et al. BMA031, a monoclonal antibody suited to identify the T-cell receptor alpha beta/CD3 complex on viable human T lymphocytes in normal and disease states. Hum Immunol 1990; 29: 175–88
   PubMed Web of Science ®Google Scholar
• Borst J, van Dongen JJ, Devries E, et al. BMA031 a monoclonal antibody suited to identify the T-cell receptor alpha beta/CD3 complex on viable human T lymphocytes in normal and disease states. Hum Immunol 1990; 29: 175–88
   PubMed Web of Science ®Google Scholar
• Hebart H, Ehninger G, Schmidt H, et al. Treatment of steroid-resistant graft-versus-host disease after allogeneic bone marrow transplantation with anti-CD3/TCR monoclonal antibodies. Bone Marrow Transplant 1995; 15: 891–4
   PubMed Web of Science ®Google Scholar
• Otto M, Barfield RC, Iyengar R, et al. Human gammadelta T cells from G-CSF-mobilized donors retain strong tumoricidal activity and produce immunomodulatory cytokines after clinical-scale isolation. J Immunother 2005; 28: 73–8
   PubMed Web of Science ®Google Scholar
• Kunzmann V, Bauer E, Feurle J, et al. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000; 96: 384–92
   PubMed Web of Science ®Google Scholar
• Wilhelm M, Kunzmann V, Eckstein S, et al. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood 2003; 102: 200–6
   PubMed Web of Science ®Google Scholar
• Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105: 3051–7
   PubMed Web of Science ®Google Scholar